| Literature DB >> 32550527 |
Katherine Ehrenreich1,2, Rebecca Kriz1,3, Daniel Grossman1.
Abstract
OBJECTIVE: The objective of this content analysis was to explore the accuracy and completeness of information provided about miscarriage on consumer-facing websites. STUDYEntities:
Keywords: Early pregnancy failure; Early pregnancy loss; Health information; Miscarriage; Spontaneous abortion
Year: 2019 PMID: 32550527 PMCID: PMC7286151 DOI: 10.1016/j.conx.2019.100010
Source DB: PubMed Journal: Contracept X ISSN: 2590-1516
Key messages from ACOG Practice Bulletin on Early Pregnancy Loss
| Message title | Message content | |
|---|---|---|
| Definition | Nonviable, intrauterine pregnancy with either an empty gestational sac or a gestational sac containing an embryo or fetus without fetal heart activity within the first 12 6/7 weeks of gestation. | |
| Incidence | Miscarriage occurs in 10% of all clinically recognized pregnancies, and approximately 80% of all pregnancy loss occurs in the first trimester. | |
| Risk factors | Common | • 50% of miscarriages are due to fetal chromosome abnormalities. |
| Other | • Genetic polymorphism. | |
| Symptoms | Similar to normal pregnancy symptoms, ectopic pregnancy and molar pregnancy (e.g., vaginal bleeding and cramping). | |
| Diagnosis | Evaluation with ultrasound | Ultrasonography is preferred modality to verify the presence of a viable intrauterine gestation, along with medical history, physical examination and serum β-hCG. |
| Needing additional time | In some instances, a single serum β-hCG or ultrasound may not be sufficient, and additional time and tests may be needed. | |
| Other clinical factors | It is important to include the patient in the diagnostic process and to individualize these guidelines to patient circumstances. | |
| Treatment | Expectant management/watchful waiting | • Limited to first trimester, 80% effective within 8 weeks. |
| Medical management | •Treatment with misoprostol administered orally, vaginally or sublingually. | |
| Medical management dosing | •Recommended initial dose of misoprostol is 800 mcg vaginally. One repeat dose may be administered as needed, no earlier than 3 h after the first dose and typically within 7 days if there is no response to the first dose. | |
| Medical management follow-up | •Follow-up to document the complete passage of tissue can be accomplished by ultrasound examination, typically within 7–14 days. | |
| Surgical management | •May be preferable for women with any comorbidities (anemia, cardiovascular disease) and used in urgent situations like hemorrhage or signs of infection. | |
| Choice | Patient preference should be strongly considered, and patients should be counseled about the risks and benefits of each option. | |
| Risks | While very rare, intrauterine adhesion formation can occur with surgical management, and hemorrhage and infection can occur with any of the treatment options. | |
| After miscarriage | Conception | There are no quality data to support delaying conception after miscarriage to prevent subsequent miscarriages or other pregnancy complications. |
| Intercourse | Generally recommended to abstain from vaginal intercourse for 1–2 weeks after complete passage of the pregnancy tissue to avoid infection, although not evidence based. | |
| Contraception | Contraception can be initiated immediately after an early pregnancy loss if pregnancy avoidance is desired. Intrauterine devices can be placed immediately after surgical treatment. | |
| Management of Rh(D) negative patients | Patients who are Rh(D) negative and unsensitized should receive a shot of Rh(D) immediately after surgical management of pregnancy loss or within 72 h of the diagnosis of early pregnancy loss with planned medical management or expectant management in the first trimester. | |
| Repeat miscarriage | Patients who have experienced at least three prior pregnancy losses may benefit from progesterone therapy in the first trimester. Additional workup or testing may be done if a woman has more than two early pregnancy losses. | |
| Preventing miscarriage | There are no effective interventions to prevent miscarriage. Bed rest should not be recommended for the prevention of miscarriage. Women who have experienced at least three prior pregnancy losses may benefit from progesterone therapy in the first trimester. | |
| Emotional response | Some women report emotional difficulty after miscarriage and may benefit from counseling or support groups. | |
Other risk factors were not included in the ACOG Practice Bulletin itself, and were cited in the references of the Practice Bulletin
Use of medication added by authors, not included in ACOG Practice Bulletin
The use of mifepristone combined with misoprostol for medical management of miscarriage was incorporated into the ACOG Practice Bulletin in November 2018
Not included in ACOG Practice Bulletin.
Accuracy of website content
| Key messages ( | WebMD | NIH | Mayo Clinic | Medicine Net | Drugs. com | Everyday Health | Healthline | Rx List | Medical News Today | ACNM | ACOG Patient Education | Mean | Number of websites including key message |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Definition | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 3 | 11 (100) | |
| Incidence | 2 | 3 | 2 | 2 | 2 | 3 | 2 | 2 | 2 | 3 | 3 | 11 (100) | |
| Risk factors | |||||||||||||
| Common risk factors | 3 | 3 | 3 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2.9 | 11 (100) |
| Other risk factors | 3 | 3 | 3 | 0 | 3 | 0 | 3 | 3 | 2 | 3 | 3 | 2.4 | 9 (82) |
| Symptoms | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 3 | 11 (100) | |
| Diagnosis | |||||||||||||
| Evaluation with ultrasound | 2 | 3 | 3 | 3 | 3 | 3 | 0 | 3 | 3 | 3 | 3 | 2.6 | 10 (91) |
| Needing additional time | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 3 | 0.5 | 2 (18) |
| Other clinical factors | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0.3 | 1 (9) |
| Treatment | |||||||||||||
| Expectant management/watchful waiting | 0 | 3 | 3 | 3 | 3 | 3 | 3 | 1 | 3 | 3 | 2 | 2.5 | 10 (91) |
| Medical management | 3 | 3 | 2 | 0 | 3 | 3 | 0 | 0 | 0 | 3 | 3 | 1.8 | 7 (64) |
| Medical management dosing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0 (0) |
| Medical management follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 0.4 | 2 (18) |
| Surgical management | 1 | 2 | 3 | 3 | 3 | 3 | 0 | 1 | 3 | 2 | 3 | 2.2 | 10 (82) |
| Treatment choice | 3 | 0 | 3 | 0 | 3 | 3 | 0 | 0 | 0 | 3 | 2 | 1.5 | 6 (55) |
| Treatment risks | 0 | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 1.0 | 4 (36) |
| After miscarriage | |||||||||||||
| Conception | 1 | 2 | 3 | 2 | 1 | 0 | 1 | 2 | 0 | 2 | 3 | 1.5 | 9 (82) |
| Intercourse | 3 | 0 | 3 | 0 | 0 | 0 | 1 | 0 | 0 | 3 | 3 | 1.2 | 5 (45) |
| Contraception | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 0.8 | 3 (27) |
| Rh(D) management | 3 | 0 | 0 | 3 | 0 | 0 | 0 | 3 | 0 | 2 | 3 | 1.3 | 5 (45) |
| Repeated miscarriage | 2 | 3 | 3 | 2 | 3 | 3 | 0 | 3 | 0 | 3 | 3 | 9 (82) | |
| Preventing miscarriage | 2 | 2 | 3 | 2 | 2 | 3 | 1 | 2 | 2 | 0 | 3 | 10 (91) | |
| Emotional response | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 11 (100) | |
| Mean score | |||||||||||||
| Key messages included ( |
Completeness of website content
| Key messages ( | WebMD | NIH | Mayo Clinic | Medicine Net | Drugs. com | Everyday Health | Healthline | Rx List | Medical News Today | ACNM | ACOG Patient Education | Mean | Number of websites including key message ( |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Definition | 3 | 3 | 2 | 3 | 2 | 1 | 2 | 3 | 3 | 2 | 2 | 11 (100) | |
| Incidence | 3 | 2 | 3 | 3 | 3 | 2 | 3 | 3 | 3 | 2 | 2 | 11 (100) | |
| Risk factors | |||||||||||||
| Common risk factors | 3 | 3 | 3 | 3 | 1 | 2 | 3 | 3 | 1 | 3 | 2 | 2.5 | 11 (100) |
| Other risk factors | 3 | 3 | 3 | 0 | 3 | 0 | 2 | 3 | 3 | 2 | 1 | 2.1 | 9 (82) |
| Symptoms | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 3 | 3 | 3 | 3 | 11 (100) | |
| Diagnosis | |||||||||||||
| Evaluation with ultrasound | 2 | 3 | 3 | 3 | 3 | 2 | 0 | 3 | 3 | 2 | 3 | 2.5 | 10 (91) |
| Needing additional time | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 3 | 0.5 | 2 (18) |
| Other clinical factors | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0.1 | 1 (9) |
| Treatment | |||||||||||||
| Expectant management/watchful waiting | 0 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1.4 | 10 (91) |
| Medical management | 1 | 1 | 2 | 0 | 1 | 1 | 0 | 0 | 0 | 2 | 1 | 0.8 | 7 (64) |
| Medical management dosing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0 (0) |
| Medical management follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 2 | 0.5 | 2 (18) |
| Surgical management | 1 | 1 | 2 | 1 | 1 | 1 | 0 | 1 | 1 | 2 | 3 | 1.3 | 10 (82) |
| Treatment choice | 1 | 0 | 1 | 0 | 1 | 3 | 0 | 0 | 0 | 3 | 2 | 1.0 | 6 (55) |
| Treatment risks | 0 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0.5 | 4 (36) |
| After miscarriage | |||||||||||||
| Conception | 1 | 2 | 3 | 2 | 1 | 0 | 1 | 2 | 0 | 3 | 3 | 1.6 | 9 (82) |
| Intercourse | 1 | 0 | 3 | 0 | 0 | 0 | 1 | 0 | 0 | 3 | 2 | 0.9 | 5 (45) |
| Contraception | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 0.6 | 3 (27) |
| Rh(D) | 2 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 0 | 2 | 2 | 0.9 | 5 (45) |
| Repeated miscarriage | 2 | 2 | 3 | 2 | 3 | 2 | 0 | 2 | 0 | 2 | 2 | 9 (82) | |
| Preventing miscarriage | 3 | 2 | 3 | 2 | 2 | 2 | 1 | 2 | 2 | 0 | 2 | 10 (91) | |
| Emotional response | 3 | 1 | 3 | 3 | 3 | 2 | 3 | 1 | 1 | 3 | 3 | 11 (100) | |
| Mean score | |||||||||||||
| Key messages included ( |